April 04, 2026 11:51 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Not denied a ticket’: Annamalai explains absence from BJP’s Tamil Nadu candidate list | ‘Ghar-wapsi soon’: PoK wants to return to India, claims Imam organisation chief | Kerala polls shocker: Tharoor’s convoy stopped, security guard attacked mid-campaign | AAP drops Raghav Chadha from key parliamentary role, sparks buzz over internal rift | Amit Shah to camp in West Bengal for 15 days during Assembly polls; predicts Mamata’s defeat in state and Bhabanipur | 'BJP plotting President’s Rule, don’t fall in the trap': Mamata Banerjee on Malda unrest, urges peace | 'Most polarised state': CJI Kant raps Bengal govt over 9-hour hostage of judicial officers | Bengal SIR protest: Judge pleads for help amid mob attack after 9-hour hostage ordeal | Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow
India | COVID vaccines
Image Credit: Unsplash

In a big boost, Covaxin, Covishield get full market authorisation

| @indiablooms | Jan 20, 2022, at 06:12 am

New Delhi/IBNS: In a big boost to India's fight against COVID-19, an expert panel of the central drug authority on Wednesday cleared the country's two indigenous vaccines-Covaxin and Covishield-for full use.

The development comes a year after these vaccines' administration on an emergency-use basis started in India.

With this move, the vaccines are expected to be widely available at hospitals and clinics soon, which are registered with the government portal CoWIN.

This will also aid in booster doses, which Prime Minister Narendra Modi announced last month to be administered on health and frontline workers and adults above 60 years of age, as precautionary third doses.

The recommendation by the expert panel of the Central Drugs Standard Control Organisation (CDSCO) has been sent to the top drug regulator DGCI.

"SEC of CDSCO has recommended for the upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision," the regulatory body tweeted.

India’s COVID-19 vaccination coverage has crossed 159.54 Crore on Wednesday, the Union Health Ministery stated.

More than 62 lakh vaccine doses have been administered till 7 pm. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.